Arqule Inc Watch

from 10-Q 2 pages (A) a Lump Sum Payment in the Amount Equal to the Sum of (I) Your Then-In-Effect Base Salary Through the End of the Twelve (12) Month Period Commencing on the Date of Termination and (II) One Year’s Bonus Calculated Based on the Average of the Bonuses, if Any, Paid by the Company to You With Respect to the Two (2) Years Preceding the Year in Which the Date of Termination Occurs, Provided That, for Purposes of This Paragraph Only, You Shall Be Deemed to Have Received Your 35 Percent Bonus Target for Any Year Within Such 2-Year Period in Which You Were Not Paid a Bonus Solely Because You Were Not Employed by the Company; and (B) Any Stock Option Held by You Shall Become Immediately Exercisable as to All Option Shares Without Regard to the Vesting Schedule Set Forth on the Applicable Option Certificate, and Any Shares of Restricted Stock Previously Granted Shall Immediately Be Free and Clear of Any Restrictions

from 10-Q 2 pages Fifth Amendment to Employment Agreement

from 10-Q 2 pages Sixth Amendment to Employment Agreement

from 10-Q 2 pages Fifth Amendment to Employment Agreement

from 10-Q 8 pages The Purpose of This Letter Agreement (The “Agreement”) Is to Confirm the Terms Regarding Your Separation of Employment With Arqule, Inc.1 (“Arqule” or the “Company”). as More Fully Set Forth Below, Arqule Desires to Provide You With Severance Pay and Severance Benefits Described Herein in Exchange for Certain Agreements by You. This Agreement Will Become Effective and Enforceable on the Eighth Day After You Sign It (The “Effective Date”)

from 10-K 4 pages Arqule, Inc. 2014 Equity Incentives Plan (“Plan”) Non-Qualified Stock Option Terms and Conditions

from 10-K 4 pages Arqule, Inc. 2014 Equity Incentives Plan (“Plan”) Incentive Stock Option Terms and Conditions

from 10-Q 88 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. ***Triple Asterisks Denote Omissions. License Agreement by Arqule, Inc. and Basilea Pharmaceutica International Limited Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. ***Triple Asterisks Denote Omissions. Execution Version Licence Agreement/Arqule, Inc

from 10-K 65 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. ***Triple Asterisks Denote Omissions. Execution Version License Agreement Dated February 2, 2018 Among Arqule, Inc., Sinovant Sciences Ltd and Roivant Sciences Ltd. Allen & Overy Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. ***Triple Asterisks Denote Omissions. Contents

from 10-Q 6 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. ***Triple Asterisks Denote Omissions. Scope of Work #2

from 10-Q 13 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. ***Triple Asterisks Denote Omissions. Scope of Work #1

from 10-Q 27 pages Master Services Agreement

from 8-K 32 pages Securities Purchase Agreement

from 8-K 28 pages Securities Purchase Agreement

from 8-K 2 pages Fourth Amendment to Employment Agreement

from 8-K 2 pages Fifth Amendment to Employment Agreement

from 8-K 2 pages Fourth Amendment to Employment Agreement

from 8-K 6 pages Arqule, Inc. 2014 Equity Incentives Plan Performance Stock Option Agreement

from 8-K 2 pages Third Amendment to Employment Agreement

from 8-K 2 pages Fourth Amendment to Employment Agreement